Streetbeat News

RHHBY

Roche Holding AG

CEO

Severin Schwan

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

35.88

Mkt cap

236B

Volume

211K

High

36.01

P/E Ratio

19.05

52-wk high

42.43

Low

35.76

Div yield

0.04

52-wk low

29.20

The FDA granted accelerated approval to BeiGene Ltd's Brukinsa, in combination with Roche Holdings AG's Gazyva, for adult patients with relapsed or refractory follicular lymphoma, marking its fifth indication in the U.S. This approval is based on the response rate and durability from the ROSEWOOD Phase 2 trial. Brukinsa's global sales reached $1.3 billion for the full year 2023, with peak annual sales estimated to be $3 billion to $4 billion. BGNE shares rose 0.94% following the announcement.

Portfolio Pulse from Vandana Singh

March 08, 2024 | 3:02 pm

Alnylam Pharmaceuticals Inc (ALNY) and Roche Holdings AG (RHHBY) announced positive results from the KARDIA-2 Phase 2 study of zilebesiran for hypertension, meeting its primary endpoint. Zilebesiran, an RNAi therapeutic, showed significant reductions in systolic blood pressure across three patient cohorts. The drug is co-developed with Roche and demonstrates a promising safety profile. A global Phase 2 study, KARDIA-3, is also underway. Despite the focus on the HELIOS-B trial for vutrisiran, analysts maintain an optimistic outlook on Alnylam, particularly for its TTR silencers, with an Outperform rating reaffirmed. ALNY shares dropped 1.22% to $148.21.

Portfolio Pulse from Vandana Singh

March 05, 2024 | 7:38 pm

Alnylam Pharmaceuticals and Roche reported that their KARDIA-2 study met its primary endpoint, showing significant blood pressure reductions with Zilebesiran when added to standard antihypertensive treatments.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 12:41 pm

A group of 11 European stocks, dubbed 'Granolas' by Goldman Sachs, has outperformed the global market with lower volatility and higher yields compared to 'The Magnificent Seven' tech stocks. These companies, operating in sectors like healthcare, pharmaceuticals, luxury goods, consumer staples, industrial manufacturing, and software technology, offer advantages such as lower valuation multiples, higher dividend yields, and less volatility. Notable companies include GSK, Roche, ASML, Nestle, Novo Nordisk, Novartis, L'Oreal, LVMH, AstraZeneca, Sanofi, and SAP. For investors interested in these stocks, ETFs like the VanEck Pharmaceutical ETF (PPH) and Pacer Trendpilot European Index ETF (PTEU) are recommended.

Portfolio Pulse from Stjepan Kalinic

February 28, 2024 | 7:43 pm

Roche Holding AG is contemplating the sale of Esbriet, a lung disease medication, due to declining sales from generic competition. The company is in preliminary talks following interest from potential buyers.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 4:40 pm

Roche Holdings AG and Novartis AG announced positive results from the Phase 3 OUtMATCH study of Xolair for treating multiple food allergies, showing increased tolerance to common allergens. The FDA approved Xolair's expanded use based on this data. NVS shares slightly declined.

Portfolio Pulse from Vandana Singh

February 26, 2024 | 3:52 pm

Roche's Genentech announced positive results from the NIH-sponsored Phase III OUtMATCH study for Xolair, showing it increased tolerance to common food allergens in individuals as young as 1 year. Following this, the U.S. FDA approved Xolair as the first medicine for people with one or more food allergies. This approval is significant given the life-threatening nature of allergic reactions and the high number of food-related anaphylaxis cases treated in U.S. emergency rooms annually.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 8:12 am

The FDA has fast-tracked the review of Sarepta Therapeutics' muscular dystrophy treatment, Elevidys, with a review goal date set for June 21, 2024. This move could potentially expand Elevidys' indication and convert its approval from accelerated to traditional, aiming for a $1B market. Sarepta, in collaboration with Roche Holdings, is working towards regulatory approval and commercialization in the U.S. and globally, respectively. Analysts see the approval as a significant milestone for Duchenne patients, potentially expanding the treatment's application and market.

Portfolio Pulse from Vandana Singh

February 16, 2024 | 6:08 pm

Wedbush initiated coverage on Monte Rosa Therapeutics Inc (NASDAQ:GLUE) with an Outperform rating and a price target of $11, highlighting the company's AI/ML-based QuEEN platform and its lead asset, MRT-2359, for cancer and autoimmune diseases. Monte Rosa's strategic collaboration with Roche Holdings AG (OTC:RHHBY) could bring in over $2 billion in milestone payments plus royalties. GLUE shares rose 14.29% to $5.44.

Portfolio Pulse from Vandana Singh

February 15, 2024 | 7:05 pm

Repare Therapeutics Inc (RPTX) announced the termination of its collaboration with Roche Holdings AG (RHHBY) for the development and commercialization of camonsertib (RP-3500), effective May 7, 2024. This decision follows a review of Roche's pipeline and external factors. Repare will regain global rights to camonsertib, which is part of the ongoing Phase 1 MYTHIC trial. Despite this, Repare has received a $40 million milestone payment from Roche and expects its funds to last into mid-2026. This is Roche's second termination within a month, having previously ended a pact with HOOKIPA Pharma Inc (HOOK) for the HB-700 program.

Portfolio Pulse from Vandana Singh

February 13, 2024 | 1:43 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.